Northern, WI  12/21/2012 (BasicsMedia)  —  Politics roil markets as we meddle in holiday trade.  Most indexes are lower by more than 1% including the Dow ETF (NYSE:DIA) and the Tech Benchmark (NASDAQ:QQQQ) are all lower this morning.  Some other movers include Research in Motion (NASDAQ:RIMM) on the downside and (HALO) and (ASCA) on the upside.

Research in Motion(NASDAQ:RIMM) – 17% after having closed the regular session on Thursday at $14.12. Were the earnings that bad? On the whole, RIM’s numbers were better than decent relative to expectations. This is even though the company continues to report losses. For that matter, Q3 showed an improvement of 22 cents versus Street estimates of 35 cents.

Likewise, the company also beat on its revenue numbers – $2.7 billion versus estimates of $2.6 billion. However, in the midst of trying to stay relevant against the likes of Amazon, Apple andGoogle, RIM made the decision to change its services fee structure. This has been the company’s most profitable revenue source and accounted for almost $1 billion in revenue during the quarter.

That’s all well and good – except, the company could offer no clear explanation of how this was going to work. Meanwhile, everything regarding RIM – including the doubling of its stock price has been hedged on BB10, which is expected to launch at the end of January. The company just may have jeopardized any degree of success BB10 might have garnered. This just might have now opened an unexpected door for Microsoft‘s Windows phone 8 to gain more traction.

After all, what is there to now be excited about if RIM has just hurt its only real source of profitability? It also does not help that RIM must now pay fees to Nokia on an “ongoing basis” as part of their recent patent-licensing dispute. This shows how RIM is experiencing pressures from all sides and the company does not seem to have any answers. Unfortunately, the stock will be punished for it.

Halozyme (NASDAQ:HALO)  +22% announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer (PFE) for the purpose of developing and commercializing products combining proprietary Pfizer biologics with Halozyme’s Enhanze technology. Enhanze is Halozyme’s proprietary drug delivery platform and is based on the Co’s patented recombinant human hyaluronidase enzyme (rHuPH20).

Under the terms of the agreement, Halozyme has granted to Pfizer a worldwide license to develop and commercialize products combining rHuPH20 with Pfizer proprietary biologics directed to up to six targets.

Targets may be selected on an exclusive or non-exclusive basis. Halozyme will receive an initial payment of $8 million, which includes the upfront fee for exclusive licenses to two specified therapeutic targets in primary care and specialty care indications and the right for Pfizer to elect up to four additional targets upon payment of additional fees.

Ameristar Casinos (NASDAQ:ASCA) +18% Pinnacle Entertainment said it reached a deal to buy Ameristar Casinos for about $869 million, plus taking on its $1.9 billion in debt.  The acquisition would more than double Pinnacle’s casino and resort holdings to 17 in the United States.

Pinnacle will pay $26.50 for each share of Ameristar Casinos Inc. That’s a 20 percent premium over the company’s Thursday closing stock price of $22.07. The deal also includes $116 million in cash on hand as of Sept. 30.

 

Disclaimer:  We have no position in any stock mentioned here.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.